NEW YORK (GenomeWeb News) – Cell Signaling Technology today said that Bristol-Myers Squibb will use its PhosphoScan technology in cell and tumor phospho-profiling of a small molecule kinase inhibitor.
The PhosphoScan process involves immunoaffinity purification and tandem mass spectrometry. It will be applied to in vivo phosphorylation profiling of kinase inhibitor response profiles in xenograft tumor models.
Danvers, Mass.-based CST said that the signatures generated with the Bristol-Myers compound will be analyzed within the context of its PhosphoSignature database, which covers hundreds of cell lines and human tumors.
The firms signed this agreement following an evaluation period for the technology, which ended in March 2007.
Terms of the alliance were not disclosed.